Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001785530-21-000046
Filing Date
2021-11-01
Accepted
2021-11-01 16:11:32
Documents
2
Period of Report
2021-10-28

Document Format Files

Seq Description Document Type Size
1 FORM 3 wf-form3_163579746858156.html 3  
1 FORM 3 wf-form3_163579746858156.xml 3 1699
2 M. CHATTERJEE POA ex-24.htm EX-24 4327
  Complete submission text file 0001785530-21-000046.txt   7435
Mailing Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138 617-952-0555
Werewolf Therapeutics, Inc. (Issuer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O EDITAS MEDICINE, INC. 1 MAIN STREET CAMBRIDGE MA 02142
Business Address
Chatterjee Meeta (Reporting) CIK: 0001835388 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40366 | Film No.: 211367262